{
    "title": "R42960",
    "content": "The Hatch-Waxman Act of 1984 reformed patent and food and drug laws to balance innovation and competition in the pharmaceutical industry. Congressional focus has shifted to pharmaceutical patent litigation settlements, where brand-name companies enforce patents against generic competitors through federal court litigation. This can result in blocking generic competition or opening the market to generic entry. Pharmaceutical patent litigation can end in judgments of infringement or invalidity, leading to generic entry or blocking competition. Settlements may involve brand-name companies paying generic firms to delay market entry, termed \"reverse\" or \"pay-for-delay\" payments. Views on these settlements vary, with some attributing them to the Hatch-Waxman Act's patent litigation procedures. Reverse payment settlements in pharmaceutical patent litigation have sparked differing views among commentators. Some see them as a result of the Hatch-Waxman Act's procedures, while others view them as anti-competitive. Congress mandated notification of these settlements to antitrust authorities since 2003, but has not set specific standards for assessing their validity. The U.S. Supreme Court's 2013 decision in Federal Trade Commission v. Actavis, Inc. established that the legality of these settlements should be evaluated under the \"rule of reason\" approach. The U.S. Supreme Court's 2013 decision in Federal Trade Commission v. Actavis, Inc. established that reverse payment settlements in pharmaceutical patent litigation should be evaluated under the \"rule of reason\" approach. Legislation before Congress, such as the Preserve Access to Affordable Generics Act (S. 214) and the FAIR Generics Act (S. 504), aims to address these settlements, but has not been enacted yet. This report analyzes innovation and competition policy issues related to pharmaceutical patent litigation settlements. This report discusses innovation and competition policy issues in pharmaceutical patent litigation settlements, including reverse payment settlements and their status under antitrust laws. It also covers the process of submitting patent applications to the USPTO and the criteria for obtaining a patent. When submitting a patent application to the USPTO, inventors must draft a claim that distinctly points out their invention. The examiner will assess if the invention meets patentability criteria such as novelty and nonobviousness. Novelty requires the invention to not be fully anticipated by prior knowledge, known as \"prior art.\" Nonobviousness means the invention must not have been easily achievable based on prior knowledge. If granted, the patent owner gains exclusive rights for twenty years from the filing date to prevent others from using, selling, or importing the invention. The patent title grants inventors exclusive rights to their invention for twenty years, allowing them to exclude others from using, selling, or importing it. This exclusivity enables inventors to profit from their invention by charging higher prices. Patent owners are responsible for monitoring competitors and may need to litigate to enforce their rights. However, owning a patent does not automatically allow distribution of the product to the public. The FDA must approve the distribution of pharmaceutical products, requiring developers to conduct preclinical and clinical investigations. Generic drug manufacturers had to file their own NDA before the Hatch-Waxman Act. The Hatch-Waxman Act was enacted in response to concerns about the costly and time-consuming process for generic drug approval by the FDA. Some generic manufacturers had to prove the safety and efficacy of their products, even though they were chemically identical to previously approved pharmaceuticals. The Hatch-Waxman Act was created to address concerns about the lengthy and expensive process for generic drug approval by the FDA. It introduced an expedited pathway for generic drugs called an Abbreviated New Drug Application (ANDA), allowing generic manufacturers to demonstrate bioequivalence to pioneer drugs without extensive clinical data. This Act aimed to strike a balance between brand-name and generic pharmaceutical companies. The Hatch-Waxman Act introduced an expedited pathway for generic drugs through an Abbreviated New Drug Application (ANDA). It allows generic manufacturers to market their FDA-approved bioequivalent drugs after relevant patents expire, with a maximum extension period of five years. This extension compensates brand-name firms for the proprietary data generated during pre-clinical and clinical trials. The Hatch-Waxman Act established procedures for resolving patent disputes related to generic drug marketing applications. NDA applicants must list patents they believe would be infringed by generic drugs in the \"Orange Book.\" Generic manufacturers must certify their views on these patents when seeking approval. The Hatch-Waxman Act established procedures for resolving patent disputes related to generic drug marketing applications. An ANDA applicant must engage in a specialized certification procedure with respect to Orange Book-listed patents, including paragraph I, II, III, and IV certifications. Approval for ANDAs certified under paragraphs I or II is immediate, while those with a paragraph III certification must wait for the brand-name drug's listed patent to expire. Filing an ANDA with a paragraph IV certification constitutes an act of patent infringement under the Hatch-Waxman Act. The Hatch-Waxman Act allows generic drug manufacturers to challenge brand-name drug patents by filing an ANDA with a paragraph IV certification. This can lead to patent infringement litigation, but the first generic applicant to file a paragraph IV certification may receive a 180-day exclusivity period. This exclusivity period can result in higher profits due to limited competition in the market. The Hatch-Waxman Act allows generic drug manufacturers to challenge brand-name drug patents by filing an ANDA with a paragraph IV certification. The first applicant may receive a 180-day exclusivity period, but forfeiture events can lead to relinquishment of this exclusivity. These events include failure to market promptly, failure to obtain FDA approval in a timely manner, and expiration of certified patents. The goal is to prevent 'parking' of exclusivity and prompt market entry by generic manufacturers. The Hatch-Waxman Act allows generic drug manufacturers to challenge brand-name drug patents through paragraph IV certifications. If a patent infringement suit is brought by the brand-name company, the court may issue an injunction preventing the generic company from marketing the product. However, if the court rules in favor of the generic firm, they can launch their product once the FDA approves their ANDA. The Hatch-Waxman Act allows generic drug manufacturers to challenge brand-name drug patents through paragraph IV certifications. If a patent infringement suit is brought by the brand-name company, the court may issue an injunction preventing the generic company from marketing the product. However, if the court rules in favor of the generic firm, they can launch their product once the FDA approves their ANDA. In pharmaceutical patent litigation, settlements may occur where the generic firm agrees not to challenge the patent or produce a generic version of the drug in exchange for compensation from the NDA holder. Opinions on these settlements' impact on social welfare vary, with some considering them anticompetitive. Some believe reverse payment settlements in pharmaceutical patent litigation are anticompetitive, as they may restrict output and share profits. Others see settlements as promoting settlement, avoiding litigation expenses, and preserving judicial resources. Settlements involve an exchange of benefits between rational actors. Reverse payment settlements in pharmaceutical patent litigation involve an exchange of benefits and obligations between rational actors. These settlements may allow for generic competition before the patent expires, potentially benefiting consumers. The Hatch-Waxman Act establishes dispute settlement procedures in this context. Reverse payment settlements in pharmaceutical patent litigation, allowed under the Hatch-Waxman Act, may benefit consumers by allowing generic competition before the patent expires. These settlements alter the traditional balance of risks between the plaintiff-patentee and accused infringer, potentially leading to compensation to avoid infringement consequences. The Hatch-Waxman Amendments allow generic manufacturers to challenge patent validity without risking infringement damages. Reverse payment settlements in pharmaceutical patent litigation have led to unique procedures under the Act. Congressional action on pharmaceutical patent settlements has been limited, with the 2003 Medicare Prescription Drug Act mandating DOJ and FTC oversight of certain patent settlement agreements. In the 2003 Medicare Prescription Drug, Improvement, and Modernization Act (MMA), Congress mandated that the DOJ and FTC receive copies of certain patent settlement agreements in the pharmaceutical field. The filing requirement applies to agreements executed on or after January 7, 2004, between an ANDA applicant and either the NDA holder or an owner of an Orange Book-listed patent. Agreements related to the manufacture, marketing, or sale of brand-name or generic drugs, or the 180-day generic exclusivity period trigger the notification requirement. Certain agreements, such as purchase orders or employment contracts, are exempt from this filing requirement. The FTC received 140 final resolutions of patent disputes in FY2012, with 40 settlements possibly involving pay-for-delay payments. The MMA imposed a filing obligation on certain patent settlements in the pharmaceutical industry, but did not establish substantive standards for their validity. Various parties claimed that some reverse payment settlements violated antitrust laws, leading to different court outcomes based on general antitrust principles. This report discusses antitrust law concepts and judicial opinions on reverse payment settlements. The report discusses antitrust laws and judicial opinions on reverse payment settlements, which are considered anti-competitive conduct. The antitrust laws, including the Sherman Act and Clayton Act, prohibit certain economic conduct that restrains trade. The courts apply the \"rule of reason\" to determine if conduct constitutes an unreasonable restraint of trade. The courts interpret antitrust laws to prohibit unreasonable restraints of trade, using the \"rule of reason\" to assess if a practice imposes an unreasonable restraint on competition. Per se illegality applies to restraints with predictable anticompetitive effects. The Supreme Court has established that certain agreements or practices are conclusively presumed to be illegal without detailed inquiry, such as price fixing and group boycotts. Courts may also use a \"quick look\" approach to assess antitrust violations, requiring defendants to justify their practices. Antitrust approaches to reverse payment settlements in pharmaceutical patent litigation vary among courts. The defendant must show pro-competitive justifications to avoid antitrust liability for reverse payment settlements in pharmaceutical patent litigation. Courts differ in their approaches, with some like the Sixth Circuit deeming such agreements as per se invalid, while others like the Second, Eleventh, and Federal Circuits allow them under certain conditions. Reverse payment settlements in pharmaceutical patent litigation have been a topic of debate among courts. While some, like the Sixth Circuit, view them as per se invalid, others, including the Second, Eleventh, and Federal Circuits, permit them as long as they do not exceed the scope of the patent. For example, in Valley Drug Co. v. Geneva Pharmaceuticals, Inc., the Eleventh Circuit ruled that antitrust scrutiny should only apply to portions of the agreement that go beyond the protections of the brand-name firm's patent. This \"scope of the patent\" approach allows for reverse payment settlements under certain conditions. The Court of Appeals for the Third Circuit rejected the \"scope of the patent\" approach in antitrust scrutiny of reverse payment settlements in pharmaceutical patent litigation. They argued that this approach improperly restricts the application of antitrust law and goes against the policies of the Hatch-Waxman Act and Supreme Court precedent on patent litigation and competition. The Third Circuit believed that courts had placed too much emphasis on the presumption of validity of granted patents, which they stated was just a procedural device and not a substantive right of the patent holder. The Third Circuit rejected the \"scope of the patent\" test in antitrust scrutiny of reverse payment settlements in pharmaceutical patent litigation. They adopted a \"quick rule of reason\" test that presumed reverse payments were anticompetitive, allowing parties to rebut this by showing pro-competitive benefits. This conflict led the Supreme Court to hear the case of Federal Trade Commission v. The Supreme Court heard the case of Federal Trade Commission v. Actavis, Inc. regarding reverse payment settlements in pharmaceutical patent litigation. The Court held that such settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal under a \"quick look\" analysis. Solvay Pharmaceuticals, the NDA holder of ANDROGEL\u00ae, settled with generic firms Actavis and Paddock Laboratories, who received money in exchange for delaying the marketing of their products. The FTC charged the parties with violating the Federal Trade Commission Act. The FTC charged Solvay Pharmaceuticals and generic firms with violating the Federal Trade Commission Act by agreeing to delay marketing their products until August 31, 2015, 65 months before Solvay's patent expired. The Eleventh Circuit initially ruled in favor of the settling parties, but the Supreme Court reversed the decision in a 5-3 ruling, stating that the anticompetitive effects of the agreement fell within the scope of the patent but did not immunize it from antitrust scrutiny. The Supreme Court reversed the decision of the Eleventh Circuit regarding the agreement between Solvay and generic firms. Justice Breyer emphasized that antitrust scrutiny should not be exempted solely based on patent rights, as agreements may harm competition. The Court highlighted that patent-related settlements can violate antitrust laws. The Supreme Court reversed the Eleventh Circuit's decision on Solvay's agreement with generic firms, emphasizing that antitrust scrutiny should not be exempted based solely on patent rights. Patent-related settlements can violate antitrust laws by considering traditional antitrust factors like anticompetitive effects, market power, and legal considerations related to patents. The Hatch-Waxman Act's structure supports subjecting reverse payment settlements to antitrust scrutiny. Justice Breyer acknowledged the judicial policy favoring dispute settlement but cited five considerations supporting a contrary view. The Supreme Court reversed the Eleventh Circuit's decision on Solvay's agreement with generic firms, emphasizing that antitrust scrutiny should not be exempted based solely on patent rights. Justice Breyer cited five considerations supporting subjecting reverse payment settlements to antitrust scrutiny, outweighing the desirability of settlements that led to near-automatic antitrust immunity. The Eleventh Circuit provided near-automatic antitrust immunity to reverse payment settlements. Justice Breyer rejected the idea of presumptively unlawful settlements and emphasized the need for traditional rule of reason analysis to establish antitrust liability. Chief Justice Roberts, along with Justices Scalia and Thomas, dissented, arguing that reverse payment settlements violate antitrust law only under specific conditions. The Supreme Court concluded that the FTC must establish antitrust liability using the traditional rule of reason analysis. Chief Justice Roberts, along with Justices Scalia and Thomas, dissented, stating that reverse payment settlements violate antitrust law only under specific conditions. The dissenters expressed concerns about the potential impact on generic firms challenging patents and the protection of innovators. The Actavis decision does not eliminate the ability to settle litigation under the Hatch-Waxman Act, but parties must carefully structure and explain their agreements. Existing agreements will require lower courts to apply the rule of reason in Hatch-Waxman cases. The lower courts are tasked with applying the rule of reason in Hatch-Waxman cases regarding pharmaceutical patent litigation. Justice Breyer believes antitrust cases won't always involve examining patent validity, while the Chief Justice is concerned about the complexity and cost of resolving patent issues. Congress has options to consider, such as waiting for further judicial developments or regulating pharmaceutical patent litigation settlements. The Actavis decision addressed reverse payment settlements, but how lower courts interpret this remains to be seen. Bills in Congress, like the Preserve Access to Affordable Generics Act, aim to address reverse payment settlements. Two bills in the 113th Congress aim to regulate pharmaceutical patent litigation settlements. The Preserve Access to Affordable Generics Act, S. 27, would deem certain reverse payment settlements as acts of unfair competition. It proposes amending the Federal Trade Commission Act to presume anticompetitive effects and unlawfulness if an ANDA filer receives anything of value and agrees to limit research or sales of the product. The Fair and Immediate Release of Generics Act, S. 504, seeks to discourage reverse payment settlements by making changes to the Hatch-Waxman Act. The Fair and Immediate Release of Generics Act, S. 504, proposes changes to the Hatch-Waxman Act to discourage reverse payment settlements in pharmaceutical patent litigation. It grants generic firms rights to regulatory exclusivity and obligates them to adhere to settlement terms. Brand-name firms must decide on patent enforcement within 45 days of a challenge by a generic firm. This legislation is crucial for balancing access to new medicines and promoting competition in the pharmaceutical industry. The Hatch-Waxman Act mediates patent litigation between brand-name and generic drug companies to balance access to new medicines and promote competition in the pharmaceutical industry. Settlements that align with antitrust principles can encourage medical innovation and benefit consumers."
}